Select Medical (NYSE: SEM) shareholders approve $3.9bn buyout as founder-led consortium nears takeover
Read More Pharma Industry News InnoCare Pharma receives Chinese IND clearance for novel B7-H3 targeted ADC ICP-B794 to treat solid tumors InnoCare Pharma gains Chinese IND approval for ICP-B794, a novel B7-H3 targeted ADC for solid tumors including lung and prostate cancer. byPallavi MadhirajuJuly 7, 2025